Summit X, LLC Lineage Cell Therapeutics, Inc. Transaction History

Summit X, LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 03, 2023	SELL	$1.16 - $1.53 $4,640 - $6,120	-4,000 Reduced 26.8%	10,925 $12,000
Q2 2023 Aug 09, 2023	SELL	$1.26 - $1.53 $8,820 - $10,710	-7,000 Reduced 31.93%	14,925 $21,000
Q1 2023 May 10, 2023	SELL	$1.2 - $1.53 $9,600 - $12,240	-8,000 Reduced 26.73%	21,925 $32,000
Q4 2022 Feb 02, 2023	BUY	$1.02 - $1.5 $5,100 - $7,500	5,000 Added 20.06%	29,925 $35,000
Q3 2022 Nov 01, 2022	SELL	$1.13 - $1.77 $5,649 - $8,850	-5,000 Reduced 16.71%	24,925 $29,000
Q2 2022 Aug 12, 2022	SELL	$1.12 - $1.61 $1,120 - $1,610	-1,000 Reduced 3.23%	29,925 $48,000
Q1 2022 May 05, 2022	SELL	$1.21 - $2.48 $1,210 - $2,480	-1,000 Reduced 3.13%	30,925 $48,000
Q4 2021 Jan 19, 2022	BUY	$1.84 - $2.68 $5,520 - $8,040	3,000 Added 10.37%	31,925 $78,000
Q3 2021 Oct 19, 2021	SELL	$2.26 - $2.86 $169 - $214	-75 Reduced 0.26%	28,925 $72,000
Q2 2021 Jul 16, 2021	SELL	$2.17 - $3.0 $6,510 - $9,000	-3,000 Reduced 9.38%	29,000 $82,000
Q1 2021 May 10, 2021	BUY	$1.77 - $3.1 $1,770 - $3,100	1,000 Added 3.23%	32,000 $75,000
Q4 2020 Jan 29, 2021	BUY	$0.95 - $1.83 $1,900 - $3,660	2,000 Added 6.9%	31,000 $55,000
Q2 2020 Aug 13, 2020	SELL	$0.71 - $1.18 $1,207 - $2,006	-1,700 Reduced 5.54%	29,000 $25,000
Q1 2020 May 13, 2020	BUY	$0.6 - $1.58 $5,700 - $15,010	9,500 Added 44.81%	30,700 $25,000
Q4 2019 Jan 23, 2020	BUY	$0.54 - $1.01 $1,620 - $3,030	3,000 Added 16.48%	21,200 $19,000
Q3 2019 Oct 15, 2019	BUY	$0.85 - $1.24 $15,470 - $22,568	18,200 New	18,200 $18,000

120

94.2M

63.8K

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $91.7M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

Get notified when there are updates to the investment portfolio of Summit X, LLC, based on Form 13F filings with the SEC.

Stay updated on Summit X, LLC with notifications on news.